Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Bpo9.0
Benzoyl Peroxide – Forschung
Überwiegend Mechanismus / Beobachtung
22 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu Benzoyl Peroxide sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 2005–2026 mit einer typischen Studiengröße von 439 Teilnehmenden.
Basierend auf 22 Studien · 1 Meta-Analyse · 4 RCTs · 7,473 Teilnehmende insgesamt
Konfidenz
Mittlere Konfidenz
Nach Outcome
Skin healthDeutliche Reduktion entzündlicher und komedonaler Akneläsionen (führendes rezeptfreies Akne-Medikament); am besten in Kombination mit einem Retinoid · 4-12 weeks
Überwiegend Mechanismus / Beobachtung6 Studien
Safety profile
Überwiegend Mechanismus / Beobachtung4 Studien
Skin tone & pigmentation
Zu wenige bewertete Studien2 Studien
Depression & mood
Zu wenige bewertete Studien1 Studie
Muscle strength & power
Zu wenige bewertete Studien1 Studie
Endurance & exercise performance
Zu wenige bewertete Studien1 Studie
Women's health
Zu wenige bewertete Studien1 Studie
Men's vitality
Zu wenige bewertete Studien1 Studie
2 weitere Outcomes mit weniger Studien nicht angezeigt.
Aktives Forschungsgebiet
17 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2025
200520152026
1Beobachtungsstudien=1,012 · large study2024
Future research should consider pooled analysis of data on new emerging drugs for acne treatment (e.g. clascoterone) and focus more on acne complications.
Yuan Y, Wang Y, Xia J, Liu H, Liu JP, Li D, Wang R, Sang H, Cao H. · The Cochrane database of systematic reviews (2024)
Very low-certainty evidence suggested that benzoyl peroxide may improve investigators' global assessment (RR 1.77, 95% CI 1.37 to 2.28; 6 trials, 4110 participants, long-term treatment (12 weeks)) compared to placebo.
Thirteen trials including 4287 participants over 10 to 12 weeks suggested benzoyl peroxide may increase the risk of a less serious adverse event compared to placebo (long-term treatment), but the evidence is very uncertain (RR 1.46, 95% CI 1.01 to 2.11; very low-certainty evidence).
Benzoyl peroxide versus topical retinoids: Benzoyl peroxide may increase the percentage change in total lesion count compared to adapalene (long-term treatment), but the evidence is very uncertain (MD 10.8, 95% CI 3.38 to 18.22; 1 trial, 205 participants, 12 weeks; very low-certainty evidence).
Clinical presentation of MF resembles that of AV and other skin conditions, leading to misdiagnosis, delays in treatment, and persistence of MF in patients for years.
Draelos ZD et al. · Journal of drugs in dermatology : JDD (2026)
Clinical presentation of MF resembles that of AV and other skin conditions, leading to misdiagnosis, delays in treatment, and persistence of MF in patients for years.
This underscores the need for appropriate diagnosis and timely treatment.
Given shared pathogenic mechanisms between AV and MF, further investigation of acne topicals that target the pathogenesis of both conditions for the treatment of MF is warranted.
More recent systemic options include subantimicrobial doxycycline, sarecycline, combined oral contraceptives, spironolactone, and isotretinoin-lidose.
Hilts A, Pollard B, Tollefson M. · Pediatric clinics of North America (2026)
Acne is an inflammatory condition that can affect quality of life.
New topical treatments include tazarotene lotion, trifarotene, combined microencapsulated benzoyl peroxide and tretinoin, minocycline foam, topical dapsone, and clascoterone cream.
More recent systemic options include subantimicrobial doxycycline, sarecycline, combined oral contraceptives, spironolactone, and isotretinoin-lidose.
The strength of recommendation is lower than that of topical retinoids and benzoyl peroxide.
Balado-Simó P, Brufau-Cochs M, Morgado-Carrasco D. · Actas dermo-sifiliograficas (2026)
Several randomized clinical trials have demonstrated its efficacy and safety (with virtually no systemic adverse effects), but few have compared its effectiveness with other topical agents or its use in combination.
It is a highly interesting therapeutic alternative, particularly for patients who do not tolerate other topical treatments or in cases of acne with a strong hormonal component.
U.S. treatment guidelines conditionally recommend it for acne management due to its high cost.
Increased clinical awareness is essential to improving outcomes.
Black TA, Shen A, Rogge MN. · Dermatitis : contact, atopic, occupational, drug (2026)
While patch testing remains the primary diagnostic method, adjunctive tools such as lymphocyte transformation testing and histological evaluation may offer additional value in select cases.
Management includes topical or systemic corticosteroids and antihistamines, with surgical revision considered for refractory cases.
Alternative materials, such as noncemented implants or gentamicin-free formulations, may be appropriate for sensitized patients.
In addition to its antimicrobial action, topical therapy can also strengthen the epidermal barrier and improve the animal's well-being, especially in allergic dogs.
However, further clinical studies are required to validate the efficacy of newer agents, such as olanexidine and plant extracts.
Physical therapies such as cold plasma, fluorescence biomodulation, and low-level laser therapy have shown promising results as adjunctive options for topical therapie and wound healing promotion.
Dhawan S, Nardo CJ. · Journal of drugs in dermatology : JDD (2025)
In this review, we aim to describe what a post-BPO removal acne treatment regimen might look like based on currently approved products and products in late-stage development.
Citation: Dhawan S, Nardo CJ.
The impact on acne treatment regimens if benzoyl peroxide-containing products are removed from the market.
8Systematische Übersichtn=15 · very small study2025
Further studies should investigate whether this reduction in bacterial load translates to meaningfully lower rates of periprosthetic joint infections.
Mowers CC, Harkin WE, Williams TC, Streepy JT, Jan K, Nicholson GP, Garrigues GE. · Journal of shoulder and elbow surgery (2025)
Seven studies found their respective treatment methods to be statistically significant.
Conclusion There remains no consensus on the optimal skin preparation method immediately prior to surgery; however, acne cream applied in the days leading up to surgery has been shown to significantly reduce the bacterial load of C acnes.
The application benzoyl peroxide in the days prior to sampling showed significantly lower rates of colonization when compared to control groups in 5 separate studies.
Conclusion Cutibacterium colonization of the skin flora can be effectively reduced on the skin surface by the use of 5% BPO.
Weninger V, Agócs G, Hergár L, Váncsa S, Hegedűs B, Szerb I, Hegyi P, Skaliczki G. · EFORT open reviews (2025)
We performed a frequentist network meta-analysis and calculated pooled risk ratios (RRs) with 95% confidence interval (CI).
The use of 5% benzoyl peroxide (BPO) and its combination with the antibiotic clindamycin was found to be the most effective in reducing C. acnes colonization on the skin (BPO 5% RR = 0.25, CI: 0.08-0.72, BPO with clindamycin RR = 0.25, CI: 0.04-1.50).
Based on the rank plot, 5% BPO (P score: 0.808) was the most effective treatment, followed by BPO 5% with clindamycin (P score: 0.749).
IDP-126 is therefore recommended to be applied as a thin layer to the affected area once daily.
Gupta AK, Mann A, Vincent K, Abramovits W. · Skinmed (2024)
Cabtreo TM (1.2% clindamycin phosphate, 0.15% adapalene, and 3.1% benzoyl peroxide) or IDP-126 topical gel was approved by the US Food and Drug Administration (FDA) in October 2023 for the treatment of moderate to severe acne vulgaris in patients aged ≥12 years.
In Trial 1 (N = 183), treatment success was achieved in 49.6% (61/122) of subjects in the IDP-126 group versus 24.9% (15/61) of subjects in the vehicle group ( P < 0.01).
In Trial 2 (N = 180), treatment success was achieved in 50.5% (61/120) of subjects in the IDP-126 group versus 20.5% (12/60) of subjects in the vehicle group ( P < 0.01).
12Systematische Übersichtn=4,596 · very large study2024
The results showed that the combination of adapalene and benzoyl peroxide is a safe and effective treatment.
Sattar K, Sakina S, Mumtaz S, Behram F, Akbar A, Jadoon SK, Tasneem S. · Cureus (2024)
The Global Burden of Disease Study 2020 ranked acne vulgaris as the eighth most common skin condition, with a global estimated prevalence of 9.4%.
There were 52.8% females in the trials, and the trials reported a primary reduction of acne lesions (efficacy) from 27.5% to 70.2%.
The occurrence of adverse effects was also variable (ranging from 2.7% to 57.9%), but these effects were mild and vanished with time.
Conclusions Based on data from 9 patients, combination treatment with clascoterone cream 1% and clindamycin 1.2%/benzoyl peroxide 5% gel is safe and effective to treat patients with acne.  .
Kircik C, Kircik L, Squittieri N, Kyeremateng K. · Journal of drugs in dermatology : JDD (2026)
Background Clascoterone cream 1% is a topical androgen receptor inhibitor approved to treat acne vulgaris in patients ≥12 years of age.
This 16-week, open-label pilot study evaluated the efficacy and safety of clascoterone cream 1% combined with clindamycin 1.2%/benzoyl peroxide 5% gel in patients with acne.
Methods Patients aged ≥12 years with moderate acne applied clascoterone cream 1% twice daily and clindamycin 1.2%/benzoyl peroxide 5% gel once daily for 12 weeks.
Safety and tolerability are primary considerations when selecting ISC actives.
Bjerring P et al. · Journal of cosmetic dermatology (2026)
Safety and tolerability are primary considerations when selecting ISC actives.
Ingredients with higher irritation potential, such as retinoids and acids, should be avoided during the healing phase (on treatment day and during short-term aftercare) due to risk of irritation, as well as post-inflammatory hyperpigmentation in skin of color.
Preoperative surgical preparation was not effective at decreasing the burden of C acnes from the surgical site prior to THA, and different skin preparations should be considered.
Barton KI, Johnson RM, Miner TM, Yang CC, Dennis DA, Jennings JM. · The Journal of arthroplasty (2025)
Methods Patients were recruited and randomized into either: 1) standard (STD) surgical preparation (4% chlorhexidine gluconate); or 2) STD + benzoyl peroxide (BPO) gel (four applications of 5% BPO gel).
On the morning of the biopsy collection, a final application of 5% BPO gel was applied.
Results Of the biopsies, 11% had a positive culture.
In conclusion, the 589/1319 nm SSDW laser provided a synergistic effect as an adjunctive treatment to BPO in inflammatory acne in terms of reducing ILC and improving post inflammatory hyperpigmentation without causing discomfort or downtime.
Boonpethkaew S, Ratanapokasatit Y, Chirasuthat S, Wattanakrai P. · Archives of dermatological research (2025)
Patients were instructed to apply 2.5% benozoyl peroxide (BPO), the drug for inflammatory acne, to their entire face throughout the study.
At the 3-month follow-up, the ILC reduced by 46% on the adjunctive laser (BPO + laser) side (p = 0.0080), compared with a 29% reduction on the BPO monotherapy side (p = 0.1875).
On the adjunctive laser side, the change in ILC positively correlated with the change in melanin level (r = 0.51, p = 0.0301) and showed a trend towards a positive correlation with the change in depression volume (r = 0.45, p = 0.0606) and roughness level (r = 0.42, p = 0.0806).
Current evidence suggests that BPO as monotherapy or add-on treatment may be more effective than placebo or no treatment for improving acne, and there may be little to no difference between BPO and either adapalene or clindamycin.
Yang Z, Zhang Y, Lazic Mosler E, Hu J, Li H, Zhang Y, Liu J, Zhang Q. · Cochrane Database Syst Rev (2020)
Pooled 120 RCTs (29,592 participants); BPO more effective than placebo/no treatment for participant-reported improvement (RR 1.27, 95% CI 1.12 to 1.45)
Little to no difference between BPO and adapalene (RR 0.99) or clindamycin (RR 0.95)
Withdrawal due to adverse effects higher with BPO (RR 2.13); most common were erythema, pruritus, and burning
The fixed-dose combination gel of adapalene and BPO was significantly more effective than corresponding monotherapies, with significant differences in total lesion counts observed as early as 1 week.
Thiboutot DM, Weiss J, Bucko A, Eichenfield L, Jones T, Clark S, Liu Y, Graeber M, Kang S; Adapalene-BPO Study Group. · J Am Acad Dermatol (2007)
Pivotal 12-week double-blind RCT (n=517) of adapalene-BPO vs adapalene, BPO, or vehicle
The fixed combination was significantly more effective than either monotherapy, separating by week 1
Tolerability matched adapalene monotherapy — synergy without added irritation
Topical antimicrobial therapies performed at least as well as oral antibiotics in terms of clinical efficacy. Benzoyl peroxide was the most cost-effective and minocycline the least cost-effective therapy for facial acne.
Ozolins M, Eady EA, Avery A, Cunliffe WJ, O'Neill C, Simpson NB, Williams HC. · Health Technol Assess (2005)
Assessor-blind community RCT (n=649) in mild-to-moderate inflammatory facial acne over 18 weeks
5% BPO performed at least as well as oral oxytetracycline/minocycline and was the most cost-effective regimen
No regimen increased antibiotic-resistant strains; BPO caused more local irritation than comparators